Investing.com - Financial Markets Worldwide

Viela Bio Inc (VIE)

NASDAQ
Currency in USD
53.01
0.00(0.00%)
Closed·
Showing Viela Bio historical data. For real-time data please try another search
Day's Range
52.9953.04
52 wk Range
52.9953.04
Key Statistics
Edit
Prev. Close
53.01
Open
53.04
Day's Range
52.99-53.04
52 wk Range
52.99-53.04
Volume
-
Average Volume (3m)
0
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Viela Bio Inc News & Analysis

Show more

Viela Bio Company Profile

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company’s lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; and which is in Phase III trials for patients with myasthenia gravis and IgG4-related diseases, as well as in a Phase II trial for kidney transplant desensitization. It is also developing VIB4920, which is in a Phase II trial for kidney transplantation rejection and rheumatoid arthritis, as well as a Phase IIb trial for Sjögren’s syndrome, and VIB7734, which is in a Phase Ib trial for cutaneous lupus erythematosus, a Phase I trial for COVID-19-related acute lung injury, and a planned Phase II trial for systemic lupus erythematosus. The company’s pre-clinical research and development product candidates include VIB1116 to decrease the number and function of antigen-presenting dendritic cells; and a mAb cytokine fusion protein to inhibit inflammatory responses. Viela Bio, Inc. has a strategic collaboration with Hansoh Pharmaceutical Group Company Limited and Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in China, Hong Kong, Macau, Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was incorporated in 2017 and is headquartered in Gaithersburg, Maryland. Viela Bio, Inc. operates as a subsidiary of Amgen Inc.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
170
Market
United States

Viela Bio Inc Earnings Call Summary for Q4/2024

  • Revenue grew 5% to €44.7B; EBITDA up 5.8% to €6.788B; current net income reached record €1.53B, up 14.6%
  • EPS improved 12.4% to €2.13; proposed dividend increase of 12% to €1.40 per share; efficiency gains surpassed targets at €398M
  • Company targets 5-6% EBITDA growth in 2025, 9% increase in current net income; plans share buyback to offset employee shareholding dilution
  • CEO emphasized dual focus on resilience and growth, expressing confidence in earnings growth despite uncertain environment
  • Potential risks include supply chain disruptions, market saturation, macroeconomic pressures, regulatory changes, and currency fluctuations
Last Updated: 28-02-2025, 09:46 pm
Read Full Transcript

Earnings

Latest Release
Nov 17, 2021
EPS / Forecast
-- / -0.64
Revenue / Forecast
-- / 19.05M
EPS Revisions
a
a
Unlock
Last 90 days

VIE Income Statement

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.